In This Article:
On Friday, UCB SA (OTC:UCBJY) (OTC:UCBJF) announced further long-term data from the Phase 3 trials and their open-label extensions, investigating Bimzelx (bimekizumab) in adults with moderate-to-severe plaque psoriasis (PSO).
In a subset of 153 patients from the second extension of BE BRIGHT, 67.7% achieved complete skin clearance (PASI100+) at five years.
Among patients with PSO only at baseline, at risk of progression to psoriatic arthritis, 68.7–71.6% achieved complete skin clearance at three years, generally consistent with the overall treated group, who achieved 72%.
In this subgroup over the five years, bimekizumab was generally well tolerated with no unexpected safety findings.
Also Read: FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease
Concurrently, UCB released two-year data from the BE HEARD trials for Bimzelx in moderate to severe hidradenitis suppurativa (HS).
In 425 HS patients with ≥1 draining tunnels (DTs) at baseline, 55.7% (195/350) had no DTs at two years of treatment. 41.1% had no DTs at two years.
DTs are painful, pus-discharging tunnels under the skin resulting from long-term inflammation, frequently leading to scarring.
Among patients with one or more DTs at baseline, the proportion who had 1–2, 3–5, or >5 DTs at two years were 26.6%, 11.1%, and 6.6%, respectively.
At two years of bimekizumab treatment, 63.6% (279/439) of patients reported no or mild skin pain, compared to 10.0% (55/551) at baseline.
Price Action: UCBJY stock is down 0.87% at $102.41 at the last check Friday.
Read Next:
Image via Shutterstock
Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.
Get the latest stock analysis from Benzinga?
This article Europe-Based UCB's Bimzelx Data Reveals Sustained Skin Clearance In Inflammatory Skin Disorders originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.